Aripiprazole, Abilify Maintena Collaborative Clinical Protocol

Terminated Not Applicable NCT02717130

Study Description

An Open-label, Multi-center, Longitudinal, Within-subject Comparison Study to Evaluate the Effects of Aripiprazole Once Monthly in Subjects with Schizophrenia on 30-, 90-, and 180- day Re-hospitalization Rates Following Hospital Discharge Compared with Retrospective Re-hospitalization Rates while on Oral Antipsychotic Medication.

Study Details

Registry ID:: NCT02717130
Conditions:: Schizophrenia
Phase:: Not Applicable
Target Enrollment:: 9 participants
Start Date:: June 8, 2016
Age Range:: 18–65 years
Healthy Volunteers:: No

Study Locations (4 sites)

Washington University
St Louis, MissouriUnited States, United States
University of Missouri
Columbia, MissouriUnited States, United States
Burrell Behavioral Health
Springfield, MissouriUnited States, United States
University of Missouri
Kansas City, MissouriUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →